GlobeNewswire: F. Hoffmann-La Roche Ltd Contains the last 10 of 707 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:11:20ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/26/2852619/0/en/Roche-receives-FDA-approval-for-the-first-molecular-test-to-screen-for-malaria-in-blood-donors.html?f=22&fvtc=4&fvtv=53238Roche receives FDA approval for the first molecular test to screen for malaria in blood donors2024-03-26T16:45:00Z<![CDATA[Basel, 26 March 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) approval of the cobas® Malaria test for use on the cobas® 6800/8800 Systems. This approved test can aid healthcare professionals in reducing potential risks of patient infection from transfused blood products. The cobas Malaria test provides a highly sensitive and specific solution to help ensure that infected blood units are removed from the blood supply.]]>https://www.globenewswire.com/news-release/2024/03/12/2844516/0/en/Roche-Annual-General-Meeting-2024.html?f=22&fvtc=4&fvtv=53238Roche Annual General Meeting 20242024-03-12T12:30:00Z<![CDATA[Basel, 12 March 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 635 shareholders in attendance, who represented 77.02% of the total 106,691,000 shares, approved the Annual Financial Statements and Consolidated Financial Statements for 2023, the Remuneration Report and the Sustainability Report.]]>https://www.globenewswire.com/news-release/2024/03/12/2844516/0/fr/Assembl%C3%A9e-g%C3%A9n%C3%A9rale-2024-de-Roche.html?f=22&fvtc=4&fvtv=53238Assemblée générale 2024 de Roche2024-03-12T12:30:00Z<![CDATA[Bâle, le 12 mars 2024 ‒ Roche (SIX : RO, ROG ; OTCQX : RHHBY) a annoncé aujourd’hui l’adoption lors de son Assemblée générale ordinaire de toutes les propositions du Conseil d’administration. Les 635 actionnaires présents, représentant 77,02 % du total des 106 691 000 actions, ont approuvé les comptes annuels et les comptes consolidés pour l’exercice 2023, le rapport sur les rémunérations ainsi que le rapport sur le développement durable de l’entreprise.]]>https://www.globenewswire.com/news-release/2024/03/12/2844516/0/de/Roche-Generalversammlung-2024.html?f=22&fvtc=4&fvtv=53238Roche Generalversammlung 20242024-03-12T12:30:00Z<![CDATA[Basel, 12. März 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) gab heute bekannt, dass ihre ordentliche Generalversammlung allen Anträgen des Verwaltungsrates zugestimmt hat. Die anwesenden 635 Aktionärinnen und Aktionäre, die 77,02% der total 106'691'000 Aktien vertraten, genehmigten die Jahresrechnung und die Konzernrechnung 2023, den Vergütungsbericht sowie den Nachhaltigkeitsbericht.]]>https://www.globenewswire.com/news-release/2024/03/05/2840321/0/en/Roche-and-Alnylam-report-positive-topline-results-from-the-Phase-II-KARDIA-2-study-in-people-with-hypertension-demonstrating-clinically-significant-blood-pressure-reductions-with-z.html?f=22&fvtc=4&fvtv=53238Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care2024-03-05T12:30:00Z<![CDATA[Basel, 05 March 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase II KARDIA-2 study [NCT05103332] of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension (high blood pressure) - the leading cause of cardiovascular disease worldwide1 - met its primary endpoint. People with mild to moderate hypertension treated with zilebesiran added to a standard of care hypertension medication experienced a clinically and statistically significant reduction in systolic blood pressure at month three. Zilebesiran added to a standard of care demonstrated an encouraging safety and tolerability profile.]]>https://www.globenewswire.com/news-release/2024/02/25/2834763/0/en/New-England-Journal-of-Medicine-publishes-Phase-III-data-showing-Xolair-significantly-reduced-allergic-reactions-across-multiple-foods-in-people-with-food-allergies.html?f=22&fvtc=4&fvtv=53238New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies2024-02-25T19:00:00Z<![CDATA[Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study evaluating the efficacy and safety of Xolair® (omalizumab) in patients allergic to peanuts and at least two other common foods were published in the New England Journal of Medicine (NEJM) and featured in a late-breaking symposium at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The study showed treatment with Xolair increased the amount of peanuts, milk, egg, wheat and tree nuts (cashew, hazelnut and walnut) that it took to cause moderate to severe allergic reactions in multi-food allergic people as young as 1 year. Safety findings were consistent with the known safety profile of Xolair across its approved indications and in previous clinical trials.4 The U.S. Food and Drug Administration (FDA) recently approved the expanded use of Xolair in children and adults with IgE-mediated food allergies based on the OUtMATCH data.]]>https://www.globenewswire.com/news-release/2024/02/16/2830859/0/en/FDA-approves-Xolair-as-first-and-only-medicine-for-children-and-adults-with-one-or-more-food-allergies.html?f=22&fvtc=4&fvtv=53238FDA approves Xolair as first and only medicine for children and adults with one or more food allergies2024-02-16T16:24:38Z<![CDATA[Basel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and paediatric patients aged 1 year and older with IgE-mediated food allergy. People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as “food allergen avoidance”). Xolair should not be used for the emergency treatment of any allergic reactions, including anaphylaxis. Immunoglobulin E (IgE)-mediated food allergies are the most common type and are typically characterised by the rapid onset of symptoms following exposure to certain food allergens.3 Xolair is the first and only FDA-approved medicine to reduce allergic reactions in people with one or more food allergies. Xolair is widely available and can now be prescribed for appropriate patients with IgE-mediated food allergy in the U.S.]]>https://www.globenewswire.com/news-release/2024/02/01/2821659/0/en/New-long-term-data-for-Roche-s-Vabysmo-show-sustained-retinal-drying-and-vision-improvements-in-retinal-vein-occlusion-RVO.html?f=22&fvtc=4&fvtv=53238New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)2024-02-01T06:03:00Z<![CDATA[Basel, 1 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO).1,2 Whereas available RVO treatments are typically given every one to two months, the data showed nearly 60% of people receiving Vabysmo in BALATON and up to 48% of people in COMINO were able to extend their treatment intervals to three or four months apart.1,2,3,4 In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year. Retinal drying is an important clinical measure as swelling from excess fluid in the back of the eye has been associated with distorted and blurred vision.5 In both studies, Vabysmo was well tolerated and the safety profile was consistent with previous studies.]]>https://www.globenewswire.com/news-release/2024/02/01/2821655/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-Roche-exceeds-guidance-and-achieves-sales-growth-of-1-CER-for-2023-despite-sharp-COVID-19-sales-decline.html?f=22&fvtc=4&fvtv=53238[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline2024-02-01T06:00:00Z<![CDATA[Outlook for 2024Roche expects an increase in Group sales in the mid single digit range (at constant exchange rates). Core earnings per share are targeted to develop broadly in line with sales growth (at constant exchange rates), excluding the impact from resolution of tax disputes in 2023. Roche expects to further increase its dividend in Swiss francs.]]>https://www.globenewswire.com/news-release/2024/02/01/2821655/0/fr/Annonce-%C3%A9v%C3%A9nementielle-au-sens-de-l-art-53-RC-Roche-d%C3%A9passe-les-projections-et-affiche-une-croissance-des-ventes-de-1-TCC-en-2023-malgr%C3%A9-un-net-recul-des-ventes-li%C3%A9-au-COVID-19.html?f=22&fvtc=4&fvtv=53238[Annonce événementielle au sens de l’art. 53 RC] Roche dépasse les projections et affiche une croissance des ventes de 1 % (TCC) en 2023, malgré un net recul des ventes lié au COVID-192024-02-01T06:00:00Z<![CDATA[Prévisions pour 2024Roche table sur une augmentation du chiffre d'affaires consolidé dans la partie moyenne de la plage à un chiffre (à taux de change constants). Le bénéfice par titre rapporté aux activités de base devrait progresser globalement au même rythme que la croissance des ventes (à taux de change constants), sans tenir compte de l’incidence du règlement des litiges fiscaux en 2023. Roche table sur une nouvelle augmentation de son dividende en francs suisses.]]>